Yahoo · Oct 26, 2026
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
Biogen heads into Q3 earnings with growth from new drugs and acquisitions potentially offsetting declining multiple sclerosis sales.
SU
NASDAQ · SUPN
Supernus Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$41.84
Up+$0.08 (+0.19%)
Updated Oct 31, 2026, 1:05 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.6B
- P/E ratio
- -137.62
- Dividend yield
- 0.00%
- 52-week range
- $37.54 – $59.68
- Volume
- 1.88M
- Avg. volume
- 851.65K
Price performance · SUPN
SUPN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
SUPN closed at $41.84 after 20 trading sessions, down 1.27% for the selected period.
- Last close
- $41.84
- Period change
- -1.27%
- Period low
- $37.88
- Period high
- $43.05
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $44.24 | $44.31 | $40.75 | $41.84 | 1.88M |
| Oct 28, 2026 | $40.46 | $41.18 | $39.67 | $41.08 | 1.1M |
| Oct 27, 2026 | $40.57 | $41.20 | $39.87 | $40.96 | 1.08M |
| Oct 26, 2026 | $40.72 | $40.87 | $39.575 | $40.77 | 930.9K |
| Oct 23, 2026 | $41.68 | $41.95 | $39.9575 | $40.70 | 1.16M |
| Oct 22, 2026 | $41.52 | $42.09 | $40.73 | $42.07 | 937.42K |
| Oct 21, 2026 | $41.23 | $42.00 | $40.86 | $41.21 | 1.01M |
| Oct 20, 2026 | $39.95 | $41.74 | $39.77 | $41.23 | 1.24M |
| Oct 19, 2026 | $37.77 | $40.52 | $37.765 | $39.84 | 1.51M |
| Oct 16, 2026 | $39.49 | $39.50 | $37.54 | $37.88 | 1.44M |
| Oct 15, 2026 | $40.21 | $41.31 | $39.36 | $39.57 | 1.01M |
| Oct 14, 2026 | $41.93 | $43.26 | $39.97 | $40.18 | 906.72K |
| Oct 13, 2026 | $42.94 | $43.29 | $41.71 | $42.01 | 1.2M |
| Oct 12, 2026 | $42.67 | $43.20 | $41.90 | $42.81 | 914.56K |
| Oct 9, 2026 | $42.18 | $43.14 | $42.15 | $42.67 | 643.83K |
| Oct 8, 2026 | $42.41 | $43.405 | $41.135 | $42.14 | 684.16K |
| Oct 7, 2026 | $42.24 | $43.38 | $42.24 | $43.05 | 571.04K |
| Oct 6, 2026 | $42.86 | $43.12 | $41.40 | $42.83 | 748.26K |
| Oct 5, 2026 | $42.38 | $43.20 | $42.38 | $42.76 | 1.29M |
| Oct 2, 2026 | $42.47 | $43.15 | $41.88 | $42.38 | 739.81K |
Latest SUPN news
The latest Smart Investors Daily articles mentioning SUPN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SUPN research
Overview
Company profile and research snapshot.
Company profile
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $64.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 9, 2026 | Cantor Fitzgerald | Overweight | — |
| Dec 19, 2025 | Stifel | Hold | — |
| Oct 29, 2025 | B of A Securities | Buy | — |
| Oct 23, 2025 | TD Cowen | Buy | — |
| Oct 9, 2025 | Piper Sandler | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 24, 2026
Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own
Biotech stocks live and die on access to capital, so the Federal Reserve’s signal that interest rates may pause for now gives this high risk corner of the market some breathing room. Cheaper money can make it easier to fund drug pipelines and clinical trials, which matters if you are hunting for the next breakthrough. This article highlights three financially grounded biotech stocks that could potentially benefit from this environment. The three biotech stocks in focus below are just a small...
Yahoo · Oct 22, 2026
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benzinga · Oct 22, 2026
Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027
Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGOAdditionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
